Guangzhou unveils pharma platform for global biotech growth

Recently, the Ministry of Commerce and the Guangdong Provincial People's Government co-hosted the Guangdong special session of the "Invest in China Year" promotion event in Guangzhou.

During the event, the Guangzhou Development District Management Committee signed an agreement with China National Pharmaceutical Group, a subsidiary of Charoen Pokphand Group, to establish the country's first overseas pharmaceutical innovation platform in Huangpu district. It will focus on the introduction and transformation of international innovative medicines, and help build an international ecosystem for the biopharmaceutical industry in Guangzhou.

According to the agreement, China National Pharmaceutical and Charoen Pokphand Group will set up their southern headquarters in Huangpu and promote the construction of the overseas pharmaceutical innovation platform. The platform will introduce leading technologies and products from international biopharmaceutical companies, such as Softhale and F-Star Therapeutics, to drive global cooperation in pharmaceutical innovation. It will also accelerate the industrialization of new drug innovations, and promote the development of China's biopharmaceutical industry.

The contract signing ceremony for foreign-funded projects at the "Invest in China" event.